ATE222500T1 - Enythropoietin enthaltendes arzneimittelabgabesystem - Google Patents

Enythropoietin enthaltendes arzneimittelabgabesystem

Info

Publication number
ATE222500T1
ATE222500T1 AT93916466T AT93916466T ATE222500T1 AT E222500 T1 ATE222500 T1 AT E222500T1 AT 93916466 T AT93916466 T AT 93916466T AT 93916466 T AT93916466 T AT 93916466T AT E222500 T1 ATE222500 T1 AT E222500T1
Authority
AT
Austria
Prior art keywords
enythropoietin
delivery system
drug delivery
containing drug
zein
Prior art date
Application number
AT93916466T
Other languages
English (en)
Inventor
Howard Bernstein
Edith Mathiowitz
Eric Morrel
Avram Brickner
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25386613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE222500(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Inc filed Critical Alkermes Inc
Application granted granted Critical
Publication of ATE222500T1 publication Critical patent/ATE222500T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
AT93916466T 1992-06-11 1993-06-09 Enythropoietin enthaltendes arzneimittelabgabesystem ATE222500T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88530792A 1992-06-11 1992-06-11
PCT/US1993/005497 WO1993025221A1 (en) 1992-06-11 1993-06-09 Erythropoietin drug delivery system

Publications (1)

Publication Number Publication Date
ATE222500T1 true ATE222500T1 (de) 2002-09-15

Family

ID=25386613

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93916466T ATE222500T1 (de) 1992-06-11 1993-06-09 Enythropoietin enthaltendes arzneimittelabgabesystem

Country Status (10)

Country Link
EP (1) EP0644771B2 (de)
JP (1) JPH07507806A (de)
AT (1) ATE222500T1 (de)
AU (2) AU680422B2 (de)
CA (1) CA2136434C (de)
DE (1) DE69332222T3 (de)
DK (1) DK0644771T4 (de)
ES (1) ES2181691T5 (de)
PT (1) PT644771E (de)
WO (1) WO1993025221A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US6514533B1 (en) 1992-06-11 2003-02-04 Alkermas Controlled Therapeutics, Inc. Device for the sustained release of aggregation-stabilized, biologically active agent
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
ES2151541T3 (es) * 1992-12-02 2001-01-01 Alkermes Inc Microesferas que contienen hormona del crecimiento de liberacion prolongada.
GB9310030D0 (en) * 1993-05-15 1993-06-30 Scras Dry processed particles and process for the preparation of the same
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en) * 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
AU710504B2 (en) 1994-03-15 1999-09-23 Brown University Research Foundation Polymeric gene delivery system
FR2718642B1 (fr) * 1994-04-15 1996-07-12 Pf Medicament Microsphères biodégradables à libération contrôlée et leur procédé de préparation.
US5783214A (en) * 1994-06-13 1998-07-21 Buford Biomedical, Inc. Bio-erodible matrix for the controlled release of medicinals
ZA964814B (en) 1995-06-07 1998-02-09 Glaxo Group Ltd Peptides and compounds that bind to a receptor.
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
CA2230494A1 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
GB2316316A (en) * 1996-08-23 1998-02-25 Int Centre Genetic Eng & Bio Sustained release of erythropoietin from microspheres
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
IT1293088B1 (it) * 1997-07-10 1999-02-11 Isi Ist Sierovaccinogeno Ital Microparticelle per il rilascio controllato di molecole biologicamente attive e loro uso in terapia, profilassi e diagnostica in vitro e in
GB9817470D0 (en) * 1998-08-11 1998-10-07 Andaris Ltd Pharmaceutical formulation
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
US20010008627A1 (en) 1999-01-22 2001-07-19 Soll David R. Hiv-encoded chemoattractant
US6284283B1 (en) 1999-10-21 2001-09-04 Alkermes Controlled Therapeutics, Inc. Method of producing sub-micron particles of biologically active agents and uses thereof
IL149340A0 (en) 1999-11-18 2002-11-10 Corvas Int Inc Nucleic acids encoding endotheliases, endotheliases and uses thereof
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US8637077B2 (en) 2000-12-28 2014-01-28 Takeda Pharmaceutical Company Limited Sustained-release preparation
US6974592B2 (en) 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
MXPA05003057A (es) 2002-09-18 2006-04-18 Johnson & Johnson Metodos para aumentar la produccion de celulas madre hematopoyeticas y plaquetas.
EP1852441B1 (de) 2002-09-24 2012-03-28 The Burnham Institute Mittel zur Modulierung der EPH-Rezeptor-Aktivität
KR20110112481A (ko) 2002-11-04 2011-10-12 오션 뉴트리션 캐나다 리미티드 다중 쉘을 갖는 마이크로캡슐 및 이의 제조 방법
DE10303584A1 (de) * 2003-01-30 2004-08-12 Stauss, Robert, Dr. Verwendung von Erythropoietin (EPO) als ein Beschichtungsmaterial auf medizinischen Implantaten
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
CN102241742B (zh) 2003-08-28 2014-04-02 奥索-麦克尼尔药品公司 结合血小板生成素受体的肽和化合物
JP2007533634A (ja) * 2003-09-30 2007-11-22 アキュスフィア， インコーポレイテッド 注射、経口、または局所用の徐放性医薬製剤
US7772182B2 (en) 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US8034450B2 (en) 2005-01-21 2011-10-11 Ocean Nutrition Canada Limited Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof
US9968120B2 (en) 2006-05-17 2018-05-15 Dsm Nutritional Products Ag Homogenized formulations containing microcapsules and methods of making and using thereof
NZ573327A (en) 2006-06-05 2012-07-27 Ocean Nutrition Canada Ltd Microcapsules with improved shells
KR20150033726A (ko) 2006-07-05 2015-04-01 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
AU2008205325B2 (en) 2007-01-10 2013-09-12 Dsm Nutritional Products Ag Vegetarian microcapsules
DK2222327T3 (en) * 2007-12-28 2017-05-15 Augustinus Bader TOPICAL USE AND FORMULATION OF ERYTHROPOIETIN FOR HEALTH CARE
CA2861392C (en) 2012-01-26 2021-08-17 Christopher J. Soares Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
WO2015136527A1 (en) 2014-03-10 2015-09-17 Health Corporation - Rambam Heparanase inhibitory peptides and use thereof for treating clinical pathologies
EP3334418B1 (de) * 2015-08-10 2023-06-07 The Trustees of Princeton University Nanoverkapselung mit grasmaterialien und anwendungen davon
US20180050005A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
JP7123932B2 (ja) 2016-09-02 2022-08-23 クリストファー ジェイ． ソアレス 神経保護及び神経疾患におけるｃｇｒｐ受容体アンタゴニストの使用
CA3070442A1 (en) 2017-07-26 2019-01-31 Janssen Pharmaceutica Nv Methods of protecting vascular integrity induced by targeted radiation therapy
CA3127455A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
WO2020209920A2 (en) 2019-01-25 2020-10-15 Janssen Pharmaceutica Nv Methods of mitigating toxic effects of vesicants and caustic gas
MA54821A (fr) 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv Méthodes pour augmenter la protection contre les lésions des organes et des vaisseaux, la récupération hématopoïétique et la survie en réponse à une exposition à une irradiation corporelle totale ou à des agents chimiques
US20230104658A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica Nv Methods of increasing progenitor cell production
WO2023168426A1 (en) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197229A (ja) † 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
SE459005B (sv) † 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5057317A (en) † 1987-03-24 1991-10-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
WO1989003678A1 (en) * 1987-10-30 1989-05-05 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
FR2658432B1 (fr) * 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
JPH04124127A (ja) * 1990-09-14 1992-04-24 Chugai Pharmaceut Co Ltd マイクロカプセル型徐放性製剤及びその製造法
CA2099376A1 (en) * 1991-01-03 1992-07-04 Henry E. Auer Stabilization of proteins by cationic biopolymers
US5288502A (en) * 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres

Also Published As

Publication number Publication date
WO1993025221A1 (en) 1993-12-23
EP0644771A1 (de) 1995-03-29
JPH07507806A (ja) 1995-08-31
EP0644771B2 (de) 2006-12-06
EP0644771B1 (de) 2002-08-21
DE69332222D1 (de) 2002-09-26
DK0644771T3 (da) 2002-12-16
ES2181691T3 (es) 2003-03-01
AU4275597A (en) 1998-01-15
DE69332222T3 (de) 2007-05-10
DK0644771T4 (da) 2006-12-27
PT644771E (pt) 2002-12-31
DE69332222T2 (de) 2003-03-20
CA2136434A1 (en) 1993-12-23
ES2181691T5 (es) 2007-10-01
AU4630893A (en) 1994-01-04
CA2136434C (en) 2008-12-02
AU698016B2 (en) 1998-10-22
AU680422B2 (en) 1997-07-31

Similar Documents

Publication Publication Date Title
ATE222500T1 (de) Enythropoietin enthaltendes arzneimittelabgabesystem
PT98397A (pt) Processo para a preparacao de microcapsulas para administracao de uma composicao farmaceutica com libertacao controlada duma proteina ou dum polipeptido mediante integracao com um polimero hidrofobico biodegradavel
NO884474D0 (no) Implanterbart, biologisk nedbrytbart virkestoff-frigjoeringssystem.
FI872481A (fi) Kiinteä, hallitusti vapauttava lääkeaineen kantoaineena käytettävä matriisi
DE3762309D1 (de) Formulierungen mit verzoegerter freisetzung.
DK1028753T3 (da) Indgivelse af poly(ethylenglycol)-konjugerede molekyler fra nedbrydellige hydrogeler
FR2739564B3 (fr) Seringue de securite a usage unique, dont la canule d'aiguille se retracte automatiquement et entierement apres le premier usage
GR3030732T3 (en) Pharmaceutical compositions including a drug, a cross-linked polymeric substance, an oil, and a surface active agent.
BR0210631A (pt) Composição farmacêutica de liberação prolongada
KR910009241A (ko) 치근막 질환 치료용 서방성 조성물
ES2016620B3 (es) Sistema para liberar medicamentos con bioaceptabilidad mejorada.
BR9916882A (pt) Plataforma passiva para retenção de componentes óticos
NO953647D0 (no) Veterinær-medikament med forlenget frigjöring
ES2051706T3 (es) Agente coccidiocida.
MC2102A1 (fr) Application de micelles mixtes
FR2739563B1 (fr) Seringue de securite a usage unique, dont la canule d'aiguille se retracte automatiquement et entierement apres le premier usage

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification

Ref document number: 0644771

Country of ref document: EP

REN Ceased due to non-payment of the annual fee